Key result
Higher plasma DHA levels were significantly associated with a reduced risk of all-cause mortality in patients with acute decompensated HFpEF (HR 0.16; 95% CI 0.06-0.44; p=0.001).
Why the study?
The clinical relevance of polyunsaturated fatty acids in heart failure remains unclear, prompting investigation into their association with prognosis in patients with HFpEF.
Are plasma polyunsaturated fatty acid levels associated with all-cause mortality in patients with acute decompensated HFpEF?
Cohort (n=140)
Are plasma polyunsaturated fatty acid levels associated with all-cause mortality in patients with acute decompensated HFpEF?
Low plasma DHA levels may serve as a useful predictor of all-cause mortality in patients with acute decompensated HFpEF.
May inform prognosis via DHA levels in acute decompensated HFpEF; hypothesis-generating and requires randomized confirmation.
The clinical relevance of polyunsaturated fatty acids (PUFAs) in heart failure remains unclear. The aim of this study was to investigate the association between PUFA levels and the prognosis of patients with heart failure with preserved ejection fraction (HFpEF). This retrospective study included 140 hospitalized patients with acute decompensated HFpEF (median age 84.0 years, 42.9% men). The patients’ nutritional status was assessed, using the geriatric nutritional risk index (GNRI), and their plasma levels of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (AA), and dihomo-gamma-linolenic acid (DGLA) were measured before discharge. The primary outcome was all-cause mortality. During a median follow-up of 23.3 months, the primary outcome occurred in 37 patients (26.4%). A Kaplan–Meier analysis showed that lower DHA and DGLA levels, but not EPA or AA levels, were significantly associated with an increase in all-cause death (log-rank; p < 0.001 and p = 0.040, respectively). A multivariate Cox regression analysis also revealed that DHA levels were significantly associated with the incidence of all-cause death (HR: 0.16, 95% CI: 0.06–0.44, p = 0.001), independent of the GNRI. Our results suggest that low plasma DHA levels may be a useful predictor of all-cause mortality and potential therapeutic target in patients with acute decompensated HFpEF.
No takes yet. Share an insight, caveat, or question.
Matsuo et al. (2021) conducted a cohort in Acute decompensated heart failure with preserved ejection fraction (HFpEF) (n=140). Plasma docosahexaenoic acid (DHA) levels vs. Lower DHA levels was evaluated on All-cause mortality (HR 0.16, 95% CI 0.06-0.44, p=0.001). Higher plasma DHA levels were significantly associated with a reduced risk of all-cause mortality in patients with acute decompensated HFpEF (HR 0.16; 95% CI 0.06-0.44; p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: